The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Safety Profile of CAR-T Cell JCAR017 in R/R Aggressive B-NHL patients
David Maloney, BSc, MD, PhD, from Fred Hutchinson Cancer Research Center, Seattle, WA, describes his poster on the safety profile of CAR-T cell JCAR017 (lisocabtagene maraleucel) in patients with relapsed/refractory aggressive B-NHL patients. He describes how JCAR017 differs from the other CAR-T cell products that exist and answers the question, ‘is there potential for outpatient administration?’ Dr Maloney feels the results presented at ASH 2017 in Atlanta, GA, where this interview was recorded, are very encouraging.
